Cargando…
Thrombosis in Myeloproliferative Neoplasms: A Single Center Experience of Using Whole Blood Platelet Aggregation Studies for Risk Assessment and Thromboprophylaxis
Thromboembolic complications are the most common causes of morbidity and mortality in patients with Philadelphia chromosome-negative myeloproliferative neoplasms (MPN); and prevention of these complications remains a significant clinical challenge. Effective thromboprophylaxis in MPN patients genera...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340402/ https://www.ncbi.nlm.nih.gov/pubmed/35898172 http://dx.doi.org/10.1177/10760296221117482 |
_version_ | 1784760395802607616 |
---|---|
author | Manoharan, Arumugam Gemmell, Rosalie Cavanaugh, Lauren Shadood, Noor |
author_facet | Manoharan, Arumugam Gemmell, Rosalie Cavanaugh, Lauren Shadood, Noor |
author_sort | Manoharan, Arumugam |
collection | PubMed |
description | Thromboembolic complications are the most common causes of morbidity and mortality in patients with Philadelphia chromosome-negative myeloproliferative neoplasms (MPN); and prevention of these complications remains a significant clinical challenge. Effective thromboprophylaxis in MPN patients generally requires use of anti-platelet therapy, commonly aspirin; however, there are no standardized or universally accepted guidelines regarding the dose of aspirin. This study evaluates the usefulness of whole blood platelet aggregation (WBPA) studies to identify patients at risk for thrombosis and to achieve safe and effective long term thromboprophylaxis. One hundred and thirty-two consecutive patients were enrolled into this study. WBPA studies were performed at diagnosis in 125 patients to identify those with platelet hyperactivity (deemed to be at risk for thrombosis) and repeated 4 weeks after commencement of anti-platelet therapy to ascertain the efficacy. In patients with incomplete drug effect, treatment was revised and the study repeated until optimum effect was achieved. Results of the WBPA studies and anti-platelet therapy requirements were correlated with the underlying driver mutations and various international prognostic score of thrombosis for essential thrombocythemia (IPSET- Thrombosis) sub-groups. WBPA studies showed varying degrees of platelet hyper-activity in 115 patients. Based on these results, the patients were commenced on anti-platelet therapy comprising aspirin (dose ranging from 100mg twice or thrice weekly to 400mg daily) and clopidogrel (75mg daily) alone or in combination with aspirin or odorless garlic. None of the patients developed thrombosis during the follow up period ranging from 1-23 years (median 8yrs), while on the prescribed, individualized anti-platelet therapy. No significant differences were noted in terms of aspirin dose requirements between the JAK-2 positive and CALR or MPL positive patients, and, among the four IPSET-Thrombosis sub-groups. Patients with normal (9) or hypo (1) – activity were not given any anti-platelet therapy at diagnosis. CONCLUSION: Routine use of WBPA studies enables safe and effective risk-adapted thromboprophylaxis in MPN patients, irrespective of the underlying driver mutation and their risk predicted by the IPSET- thrombosis criteria. |
format | Online Article Text |
id | pubmed-9340402 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-93404022022-08-02 Thrombosis in Myeloproliferative Neoplasms: A Single Center Experience of Using Whole Blood Platelet Aggregation Studies for Risk Assessment and Thromboprophylaxis Manoharan, Arumugam Gemmell, Rosalie Cavanaugh, Lauren Shadood, Noor Clin Appl Thromb Hemost Original Manuscript Thromboembolic complications are the most common causes of morbidity and mortality in patients with Philadelphia chromosome-negative myeloproliferative neoplasms (MPN); and prevention of these complications remains a significant clinical challenge. Effective thromboprophylaxis in MPN patients generally requires use of anti-platelet therapy, commonly aspirin; however, there are no standardized or universally accepted guidelines regarding the dose of aspirin. This study evaluates the usefulness of whole blood platelet aggregation (WBPA) studies to identify patients at risk for thrombosis and to achieve safe and effective long term thromboprophylaxis. One hundred and thirty-two consecutive patients were enrolled into this study. WBPA studies were performed at diagnosis in 125 patients to identify those with platelet hyperactivity (deemed to be at risk for thrombosis) and repeated 4 weeks after commencement of anti-platelet therapy to ascertain the efficacy. In patients with incomplete drug effect, treatment was revised and the study repeated until optimum effect was achieved. Results of the WBPA studies and anti-platelet therapy requirements were correlated with the underlying driver mutations and various international prognostic score of thrombosis for essential thrombocythemia (IPSET- Thrombosis) sub-groups. WBPA studies showed varying degrees of platelet hyper-activity in 115 patients. Based on these results, the patients were commenced on anti-platelet therapy comprising aspirin (dose ranging from 100mg twice or thrice weekly to 400mg daily) and clopidogrel (75mg daily) alone or in combination with aspirin or odorless garlic. None of the patients developed thrombosis during the follow up period ranging from 1-23 years (median 8yrs), while on the prescribed, individualized anti-platelet therapy. No significant differences were noted in terms of aspirin dose requirements between the JAK-2 positive and CALR or MPL positive patients, and, among the four IPSET-Thrombosis sub-groups. Patients with normal (9) or hypo (1) – activity were not given any anti-platelet therapy at diagnosis. CONCLUSION: Routine use of WBPA studies enables safe and effective risk-adapted thromboprophylaxis in MPN patients, irrespective of the underlying driver mutation and their risk predicted by the IPSET- thrombosis criteria. SAGE Publications 2022-07-27 /pmc/articles/PMC9340402/ /pubmed/35898172 http://dx.doi.org/10.1177/10760296221117482 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Manuscript Manoharan, Arumugam Gemmell, Rosalie Cavanaugh, Lauren Shadood, Noor Thrombosis in Myeloproliferative Neoplasms: A Single Center Experience of Using Whole Blood Platelet Aggregation Studies for Risk Assessment and Thromboprophylaxis |
title | Thrombosis in Myeloproliferative Neoplasms: A Single Center
Experience of Using Whole Blood Platelet Aggregation Studies for Risk Assessment
and Thromboprophylaxis |
title_full | Thrombosis in Myeloproliferative Neoplasms: A Single Center
Experience of Using Whole Blood Platelet Aggregation Studies for Risk Assessment
and Thromboprophylaxis |
title_fullStr | Thrombosis in Myeloproliferative Neoplasms: A Single Center
Experience of Using Whole Blood Platelet Aggregation Studies for Risk Assessment
and Thromboprophylaxis |
title_full_unstemmed | Thrombosis in Myeloproliferative Neoplasms: A Single Center
Experience of Using Whole Blood Platelet Aggregation Studies for Risk Assessment
and Thromboprophylaxis |
title_short | Thrombosis in Myeloproliferative Neoplasms: A Single Center
Experience of Using Whole Blood Platelet Aggregation Studies for Risk Assessment
and Thromboprophylaxis |
title_sort | thrombosis in myeloproliferative neoplasms: a single center
experience of using whole blood platelet aggregation studies for risk assessment
and thromboprophylaxis |
topic | Original Manuscript |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9340402/ https://www.ncbi.nlm.nih.gov/pubmed/35898172 http://dx.doi.org/10.1177/10760296221117482 |
work_keys_str_mv | AT manoharanarumugam thrombosisinmyeloproliferativeneoplasmsasinglecenterexperienceofusingwholebloodplateletaggregationstudiesforriskassessmentandthromboprophylaxis AT gemmellrosalie thrombosisinmyeloproliferativeneoplasmsasinglecenterexperienceofusingwholebloodplateletaggregationstudiesforriskassessmentandthromboprophylaxis AT cavanaughlauren thrombosisinmyeloproliferativeneoplasmsasinglecenterexperienceofusingwholebloodplateletaggregationstudiesforriskassessmentandthromboprophylaxis AT shadoodnoor thrombosisinmyeloproliferativeneoplasmsasinglecenterexperienceofusingwholebloodplateletaggregationstudiesforriskassessmentandthromboprophylaxis |